用3D打印技术扩大胃药物输送系统的制造方法
Imola-Rebeka Turac1, Alina Porfire1, Sonia Iurian1
1Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy "Iuliu Hatieganu", 400012 Cluj-Napoca, Romania.
Pharmaceutics
|June 27, 2024
概括
胃透药物输送系统 (GRDDS) 通过延长胃内留时间来增强药物吸收和生物可用性. 本综述强调了先进的GRDDS,包括3D打印选项及其评估方法.
科学领域:
- 制药科学 制药科学
- 药物输送技术 药物输送技术
背景情况:
- 胃阻塞药物递送系统 (GRDDS) 可以延长药物在胃中的停留时间.
- 这提高了药物具有狭窄的吸收窗口或pH敏感性的生物可用性.
- 现有的GRDDS类型包括浮式,膨胀式,粘粘性,磁性,形,离子交换和高密度系统.
研究的目的:
- 审查最近GRDDS生产技术的进展.
- 为GRDDS提供体外和体内评估方法的概述.
- 突出3D打印作为创建GRDDS的革命性技术.
主要方法:
- 关于GRDDS生产和评估的最新科学文献的综述.
- 专注于浮动,扩张和粘粘性GRDDS.
- 强调新的制造技术,特别是3D打印.
主要成果:
- GRDDS提供延长药物释放时间和增强生物可用性.
- 3D打印正在成为先进GRDDS制造的关键技术.
- 各种评估方法对于评估GRDDS性能至关重要.
结论:
- GRDDS代表了针对药物输送的重要策略.
- 对3D打印等新型生产技术的持续研究至关重要.
- 需要进行全面的评估,以确保GRDDS的有效性和安全性.
相关概念视频
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
Modified-Release Drug Delivery Systems: Overview
236
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
236
Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
Oral Drug Delivery Systems: Introduction
279
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
279
Oral Drug Delivery Systems: Continuous-Release Systems
308
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
308


